SB
Steven B. Ketchum
Executive Vice President, President of Research & Development, Chief Scientific Officer
Amarin CorporationTherapeutic Areas
Amarin Corporation Pipeline
| Drug | Indication | Phase |
|---|---|---|
| VASCEPA® / VAZKEPA® (Icosapent Ethyl) | Cardiovascular Risk Reduction | Approved |
| VASCEPA® (Icosapent Ethyl) | Severe Hypertriglyceridemia (≥500 mg/dL) | Approved |
Leadership Team at Amarin Corporation
PH
Patrick Holt
President, Chief Executive Officer, Director
AB
Aaron Berg
Executive Vice President, Chief Financial Officer
KM
Karim Mikhail
Executive Vice President, Chief Commercial Officer
MG
Mark G. Hibbard
Senior Vice President, General Counsel
PW
Per Wold-Olsen
Chairman of the Board of Directors
GM
Graham McVeigh
Board Director
MW
Michael W. Kalb
Board Director
DS
David Stack
Board Director
BB
Brittany Bradrick
Board Director